[Clinical efficacy of sairei-to in various urinary tract diseases centering on fibrosis].
A joint multi-institution study was conducted on the efficacy of Sairei-to, centering on urinary tract fibrosis. The subjects consisted of 18 patients with retroperitoneal fibrosis (including 3 women), 77 patients with plastic induration of penis, 5 patients with sclerotic lipogranuloma (all men), and 67 patients with hemorrhagic cystitis (including 6 men). As a rule, Sairei-to was administered in monotherapy for periods of 4 weeks or longer. Efficacy was most pronounced in the patients with sclerotic lipogranuloma and plastic induration of penis, with overall improvement rates (percentage of patients with ratings of effective or better) of 80% in the former and 77.9% in the latter group. The overall improvement rate in the patients with retroperitoneal fibrosis was 61.1%. In the above diseases, there were numerous patients concurrently administered drugs such as antiinflammatory enzyme preparations and corticoid preparations, and the improvement rates were somewhat higher in these patients treated concurrently with other drugs. Outstanding efficacy was also seen in hemorrhagic cystitis. Dividing the patients into irradiation and non-irradiation groups, respective overall improvement rates of 77.8% and 82.8% were obtained, with the non-irradiation group showing a slightly higher rate. The non-irradiation group showed slightly higher improvement rates in the subjects treated concurrently with drugs such as antibacterial drug. Conversely, the irradiation group showed significantly superior rates for monotherapy. Side effects such as mild gastrointestinal disturbances were seen in only 13 of 167 patients (7.8%), and the utility of this drug in treatment of the above diseases should be held in high regard.
Department of Urology, Gunma University School of Medicine.
K
K
Shida
K
K
Imamura
T
T
Katayama
T
T
Machida
T
T
Ohkawa
A
A
Ishibashi
D000328:Adult; D000368:Aged; D003556:Cystitis / Q000188:drug therapy; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D005355:Fibrosis; D006099:Granuloma / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D010411:Penile Induration / Q000188:drug therapy; D012185:Retroperitoneal Fibrosis / Q000188:drug therapy; D012598:Sclerosis; D014551:Urinary Tract / Q000473:pathology*; D014570:Urologic Diseases / Q000188:drug therapy* / Q000473:pathology
D004365:Drugs, Chinese Herbal; C080903:sairei-to